Low T leads to more aggressive prostate cancer

Low T leads to more aggressive prostate cancer


Lots of men and their doctors still believe that high testosterone levels cause “high-grade” prostate cancer.

Doctors constantly warn men that high levels of testosterone are what causes prostate cancer.

They monitor prostate cancer and testosterone levels together.

I have always disagreed.

Young men with high testosterone don’t typically get prostate cancer.

So how could high testosterone be a problem?

In fact, LOW testosterone is a problem.

Because men with low testosterone have far more health problems.

Then these health problems CAUSE low testosterone.

And those health problems and low testosterone often lead to cancer.

Here is a study that bears this out.

It’s a study performed on 117 male patients from the same doctor.

And it completely contradicts the belief that high testosterone leads to cancer.

Before proceeding with this study, the researchers thoroughly examined the medical records of these 117 patients.

Each of these patients had low levels of total and free testosterone.

Now, what does low testosterone mean here?

Well, total testosterone levels in healthily functioning men typically range between 300 ng./dl and 1050 ng.dl.

Free testosterone levels usually range from 9 ng./dl to 30 ng./dl.

And the study defined a low level of free testosterone as 1.5 ng./dl or less.

They defined a low total testosterone level as less than 300 ng./dl.

Patients with LOW testosterone had a higher incidence of prostate cancer.

This study found that in patients with low versus normal free testosterone there were at an increased risk.

They had a higher chance of having biopsies that showed cancer.

43 percent of the men who had low free testosterone ended up being diagnosed with prostate cancer.

But only 22 percent of the men with normal levels had the same results.

57 men in the study underwent prostatectomy.

The researchers performed further biopsies on the removed prostates.

These biopsies showed that the men with lower testosterone were the ones with the most aggressive cases of prostate cancer.

05.30.2017-14.36.15

Another study observed 90 other males.

Researchers divided the men into two groups.

Those from age 40 to 60 made up one group, and those age 61 to 80 made the other group.

All of the men had erectile dysfunction caused by low T, or what docs call “hypogonadism.”

Each of the men received a full screening for prostate issues before beginning treatment.

The screenings included the standard digital rectal exam (yep, finger up the butt), and blood tests to check PSA levels.

Then they received testosterone replacement to correct the low T and ED.

The men received testosterone replacement therapy in one of three forms.

Some received injections every 2 to 3 weeks.

Others received testosterone patches.

And others received clomiphene citrate 50mg to stimulate natural testosterone production.

After 2 or 3 months the 90 patients came back in for new tests.

Then the researchers checked the results.

All of the men had increased PSA levels.

Men getting testosterone. Men getting clomiphene.

All PSA results were higher.

Interestingly, men who received clomiphene citrate were the ones with the greatest increase in PSA levels.

Both of the external testosterone (patches or injections) recipients came in lower.

Nine of the men with the most elevated PSA levels underwent a prostate biopsy.

In one of the 90 men, doctors found a nodule during the finger exam.

He also underwent a prostate biopsy.

Two of these men had adenocarcinoma — that’s a form of cancer.

And one other man developed prostate cancer.

This came to a total of 3.3 percent of the men in the testosterone replacement study.

This study did show that PSA levels rise in all men receiving testosterone therapy…

But these levels do not all indicate cancer — nearly 97% didn’t get cancer.

Men with low testosterone have to be concerned with a lot of issues.

They suffer a loss of libido, lower strength, losing muscle mass, lower bone density, and feeling tired all the time.

They should also be concerned about low PSA levels.

That’s right.

Low testosterone is related to lower levels of PSA.

We are all taught that we want lower PSA levels.

We believe that the lower they are, the lower our chances of having prostate cancer.

But this low PSA level may be giving a false sense of security.

It could possibly be hiding cancer lurking in the prostate which remains undetected.

That’s because if we have low T, we may have low PSA — and have prostate cancer.

Now, it isn’t necessarily a problem.

As I’ve said many times, prostate cancer is shamefully over treated.

Most men can go without treatment and live a normal lifespan.

But in any event, relying on PSA isn’t a good idea.

Men with low T often have lower PSA readings — even when these men have prostate cancer.

Men should keep in mind that higher levels of testosterone do not relate to prostate cancer.

Instead, the link is between lower testosterone levels and the most aggressive cases of prostate cancer.

 

 


Matt Cook is editor-in-chief of Daily Medical Discoveries. Matt has been a full time health researcher for 26 years. ABC News interviewed Matt on sexual health issues not long ago. Matt is widely quoted on over 1,000,000 websites. He has over 300,000 daily newsletter readers. Daily Medical Discoveries finds hidden, buried or ignored medical studies through the lens of 100 years of proven science. Matt heads up the editorial team of scientists and health researchers. Each discovery is based upon primary studies from peer reviewed science sources following the Daily Medical Discoveries 7 Step Process to ensure accuracy.
IS LOW SERUM FREE TESTOSTERONE A MARKER FOR HIGH GRADE PROSTATE CANCER
http://www.sciencedirect.com/science/article/pii/S0022534705678123 
TESTOSTERONE TREATMENT IN HYPOGONADAL MEN: PROSTATE-SPECIFIC ANTIGEN LEVEL AND RISK OF PROSTATE CANCER
http://journals.aace.com/doi/abs/10.4158/EP.6.2.132?code=aace-site 

Be the first to comment

Leave a Reply

Your email address will not be published.